Glaukos Announces Topline Results From Its Phase 4 Trial Evaluating iDose TR With Cataract Surgery In Patients With Open-Angle Glaucoma Or Ocular Hypertension; Study Met Primary Efficacy Endpoint, Demonstrating Statistically Significant Superiority And Clinically Meaningful IOP Reduction Vs Cataract Surgery Alone

Glaukos Corporation (NYSE: GKOS) announced positive topline results from its Phase 4 trial evaluating iDose TR in conjunction with cataract surgery for patients with open-angle glaucoma or ocular hypertension. The study met its primary efficacy endpoint, showing a mean diurnal intraocular pressure (IOP) reduction of 11.1 mmHg for the iDose TR group compared to 7.4 mmHg for the surgery-alone group, with a statistically significant difference of 3.6 mmHg (p<0.0001). The iDose TR also demonstrated a favorable safety profile with no serious adverse events reported. The trial involved 149 study eyes, with 74 receiving iDose TR and 75 undergoing cataract surgery alone.